Synaptogenix, Inc. (NASDAQ:SNPX) Sees Significant Decline in Short Interest

Synaptogenix, Inc. (NASDAQ:SNPXGet Free Report) saw a significant decline in short interest in February. As of February 28th, there was short interest totalling 21,800 shares, a decline of 26.8% from the February 13th total of 29,800 shares. Based on an average daily volume of 15,000 shares, the days-to-cover ratio is currently 1.5 days. Currently, 1.6% of the shares of the stock are sold short.

Synaptogenix Trading Down 6.2 %

Shares of SNPX stock traded down $0.18 during trading hours on Friday, hitting $2.72. The company had a trading volume of 4,473 shares, compared to its average volume of 12,095. Synaptogenix has a 12 month low of $2.32 and a 12 month high of $6.22. The firm’s fifty day moving average is $3.12 and its 200 day moving average is $3.08.

Institutional Trading of Synaptogenix

An institutional investor recently bought a new position in Synaptogenix stock. Geode Capital Management LLC bought a new stake in Synaptogenix, Inc. (NASDAQ:SNPXFree Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 10,844 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned approximately 0.80% of Synaptogenix as of its most recent filing with the SEC. Institutional investors own 10.34% of the company’s stock.

About Synaptogenix

(Get Free Report)

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.

Read More

Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.